Selected article for: "clinical information and disease duration"
Author: Shao, Ziyun; Feng, Yongwen; Zhong, Li; Xie, Qifeng; Lei, Ming; Liu, Zheying; Wang, Conglin; Ji, Jingjing; Liu, Huiheng; Gu, Zhengtao; Hu, Zhongwei; Su, Lei; Wu, Ming; Liu, Zhifeng
Title: Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort study
  • Cord-id: cqaiyevs
  • Document date: 2020_10_14
    • ID: cqaiyevs
    Snippet: OBJECTIVE: Coronavirus disease 2019 (COVID‐19) outbreak is a major challenge all over the world, without acknowledged treatment. Intravenous immunoglobulin (IVIG) has been recommended to treat critical coronavirus disease 2019 (COVID‐19) patients in a few reviews, but the clinical study evidence on its efficacy in COVID‐19 patients was lacking. METHODS: 325 patients with laboratory‐confirmed critical COVID‐19 were enrolled from 4 government‐designated COVID‐19 treatment centres in
    Document: OBJECTIVE: Coronavirus disease 2019 (COVID‐19) outbreak is a major challenge all over the world, without acknowledged treatment. Intravenous immunoglobulin (IVIG) has been recommended to treat critical coronavirus disease 2019 (COVID‐19) patients in a few reviews, but the clinical study evidence on its efficacy in COVID‐19 patients was lacking. METHODS: 325 patients with laboratory‐confirmed critical COVID‐19 were enrolled from 4 government‐designated COVID‐19 treatment centres in southern China from December 2019 to March 2020. The primary outcomes were 28‐ and 60‐day mortality, and the secondary outcomes were the total length of in‐hospital and the total duration of the disease. Subgroup analysis was carried out according to clinical classification of COVID‐19, IVIG dosage and timing. RESULTS: In the enrolled 325 patients, 174 cases used IVIG and 151 cases did not. The 28‐day mortality was improved with IVIG after adjusting confounding in overall cohort (P = 0.0014), and the in‐hospital and the total duration of disease were longer in the IVIG group (P < 0.001). Subgroup analysis showed that only in patients with critical type, IVIG could significantly reduce the 28‐day mortality, decrease the inflammatory response and improve some organ functions (all P < 0.05); the application of IVIG in the early stage (admission ≤ 7 days) with a high dose (> 15 g per day) exhibited significant reduction in 60‐day mortality in the critical‐type patients. CONCLUSION: Early administration of IVIG with high dose improves the prognosis of critical‐type patients with COVID‐19. This study provides important information on clinical application of IVIG in the treatment of SARS‐CoV‐2 infection, including patient selection and administration dosage and timing.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and administration timing: 1
    • acute ards respiratory distress syndrome and long duration: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and low platelet: 1, 2, 3
    • acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome cause and long duration: 1
    • acute physiology and adaptive innate: 1
    • acute physiology and long duration: 1
    • acute respiratory virus infection and adaptive innate: 1
    • acute virus and adapt immune system: 1, 2
    • acute virus and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute virus and long duration: 1, 2, 3, 4, 5, 6, 7
    • acute virus and low platelet: 1, 2
    • acute virus infection and adaptive innate: 1, 2, 3, 4, 5
    • adaptive innate and administration timing: 1, 2
    • adaptive innate and low platelet: 1, 2